Trends of humoral immune responses to heterologous antigenic exposure due to vaccination & omicron SARS-CoV-2 infection : Implications for boosting
Background & objectives: Vaccination and natural infection can both augment the immune responses against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), but how omicron infection has affected the vaccine-induced and hybrid immunity is not well studied in Indian population. The present study was aimed to assess the durability and change in responses of humoral immunity with age, prior natural infection, vaccine type and duration with a minimum gap of six months post-two doses with either ChAdOx1 nCov-19 or BBV152 prior- and post-emergence of the omicron variant.
Methods: A total of 1300 participants were included in this observational study between November 2021 and May 2022. Participants had completed at least six months after vaccination (2 doses) with either ChAdOx1 nCoV-19 or an inactivated whole virus vaccine BBV152. They were grouped according to their age (≤ or ≥60 yr) and prior exposure of SARS-CoV-2 infection. Five hundred and sixteen of these participants were followed up after emergence of the Omicron variant. The main outcome was durability and augmentation of the humoral immune response as determined by anti-receptor-binding domain (RBD) immunoglobulin G (IgG) concentrations, anti-nucleocapsid antibodies and anti-omicron RBD antibodies. Live virus neutralization assay was conducted for neutralizing antibodies against four variants - ancestral, delta and omicron and omicron sublineage BA.5.
Results: Before the omicron surge, serum anti-RBD IgG antibodies were detected in 87 per cent participants after a median gap of eight months from the second vaccine dose, with a median titre of 114 [interquartile range (IQR) 32, 302] BAU/ml. The levels increased to 594 (252, 1230) BAU/ml post-omicron surge (P<0.001) with 97 per cent participants having detectable antibodies, although only 40 had symptomatic infection during the omicron surge irrespective of vaccine type and previous history of infection. Those with prior natural infection and vaccination had higher anti-RBD IgG titre at baseline, which increased further [352 (IQR 131, 869) to 816 (IQR 383, 2001) BAU/ml] (P<0.001). The antibody levels remained elevated after a mean time gap of 10 months, although there was a decline of 41 per cent. The geometric mean titre was 452.54, 172.80, 83.1 and 76.99 against the ancestral, delta, omicron and omicron BA.5 variants in the live virus neutralization assay.
Interpretation & conclusions: Anti-RBD IgG antibodies were detected in 85 per cent of participants after a median gap of eight months following the second vaccine dose. Omicron infection probably resulted in a substantial proportion of asymptomatic infection in the first four months in our study population and boosted the vaccine-induced humoral immune response, which declined but still remained durable over 10 months.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:157 |
|---|---|
| Enthalten in: |
The Indian journal of medical research - 157(2023), 6 vom: 01. Juni, Seite 509-518 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Batra, Gaurav [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 03.08.2023 Date Revised 11.09.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.4103/ijmr.ijmr_2521_22 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM358242215 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM358242215 | ||
| 003 | DE-627 | ||
| 005 | 20231226074328.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4103/ijmr.ijmr_2521_22 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1194.xml |
| 035 | |a (DE-627)NLM358242215 | ||
| 035 | |a (NLM)37322634 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Batra, Gaurav |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Trends of humoral immune responses to heterologous antigenic exposure due to vaccination & omicron SARS-CoV-2 infection |b Implications for boosting |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 03.08.2023 | ||
| 500 | |a Date Revised 11.09.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Background & objectives: Vaccination and natural infection can both augment the immune responses against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), but how omicron infection has affected the vaccine-induced and hybrid immunity is not well studied in Indian population. The present study was aimed to assess the durability and change in responses of humoral immunity with age, prior natural infection, vaccine type and duration with a minimum gap of six months post-two doses with either ChAdOx1 nCov-19 or BBV152 prior- and post-emergence of the omicron variant | ||
| 520 | |a Methods: A total of 1300 participants were included in this observational study between November 2021 and May 2022. Participants had completed at least six months after vaccination (2 doses) with either ChAdOx1 nCoV-19 or an inactivated whole virus vaccine BBV152. They were grouped according to their age (≤ or ≥60 yr) and prior exposure of SARS-CoV-2 infection. Five hundred and sixteen of these participants were followed up after emergence of the Omicron variant. The main outcome was durability and augmentation of the humoral immune response as determined by anti-receptor-binding domain (RBD) immunoglobulin G (IgG) concentrations, anti-nucleocapsid antibodies and anti-omicron RBD antibodies. Live virus neutralization assay was conducted for neutralizing antibodies against four variants - ancestral, delta and omicron and omicron sublineage BA.5 | ||
| 520 | |a Results: Before the omicron surge, serum anti-RBD IgG antibodies were detected in 87 per cent participants after a median gap of eight months from the second vaccine dose, with a median titre of 114 [interquartile range (IQR) 32, 302] BAU/ml. The levels increased to 594 (252, 1230) BAU/ml post-omicron surge (P<0.001) with 97 per cent participants having detectable antibodies, although only 40 had symptomatic infection during the omicron surge irrespective of vaccine type and previous history of infection. Those with prior natural infection and vaccination had higher anti-RBD IgG titre at baseline, which increased further [352 (IQR 131, 869) to 816 (IQR 383, 2001) BAU/ml] (P<0.001). The antibody levels remained elevated after a mean time gap of 10 months, although there was a decline of 41 per cent. The geometric mean titre was 452.54, 172.80, 83.1 and 76.99 against the ancestral, delta, omicron and omicron BA.5 variants in the live virus neutralization assay | ||
| 520 | |a Interpretation & conclusions: Anti-RBD IgG antibodies were detected in 85 per cent of participants after a median gap of eight months following the second vaccine dose. Omicron infection probably resulted in a substantial proportion of asymptomatic infection in the first four months in our study population and boosted the vaccine-induced humoral immune response, which declined but still remained durable over 10 months | ||
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Anti-receptor-binding domain IgG | |
| 650 | 4 | |a BBV152 | |
| 650 | 4 | |a ChAdOx1 nCoV-19 | |
| 650 | 4 | |a Omicron | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a humoral immune response | |
| 650 | 4 | |a immune imprinting | |
| 650 | 7 | |a BBV152 COVID-19 vaccine |2 NLM | |
| 650 | 7 | |a 76JZE5DSN6 |2 NLM | |
| 650 | 7 | |a ChAdOx1 nCoV-19 |2 NLM | |
| 650 | 7 | |a B5S3K2V0G8 |2 NLM | |
| 650 | 7 | |a Antibodies, Neutralizing |2 NLM | |
| 650 | 7 | |a Immunoglobulin G |2 NLM | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 700 | 1 | |a Murugesan, Deepika Rathna |e verfasserin |4 aut | |
| 700 | 1 | |a Raghavan, Sreevatsan |e verfasserin |4 aut | |
| 700 | 1 | |a Chattopadhyay, Souvick |e verfasserin |4 aut | |
| 700 | 1 | |a Mehdi, Farha |e verfasserin |4 aut | |
| 700 | 1 | |a Ayushi |e verfasserin |4 aut | |
| 700 | 1 | |a Gosain, Mudita |e verfasserin |4 aut | |
| 700 | 1 | |a Singh, Savita |e verfasserin |4 aut | |
| 700 | 1 | |a Das, Soon Jyoti |e verfasserin |4 aut | |
| 700 | 1 | |a Deshpande, Suprit |e verfasserin |4 aut | |
| 700 | 1 | |a Sonar, Sudipta |e verfasserin |4 aut | |
| 700 | 1 | |a Jakhar, Kamini |e verfasserin |4 aut | |
| 700 | 1 | |a Bhattacharya, Jayanta |e verfasserin |4 aut | |
| 700 | 1 | |a Mani, Shailendra |e verfasserin |4 aut | |
| 700 | 1 | |a Pandey, Anil Kumar |e verfasserin |4 aut | |
| 700 | 1 | |a Sankalp |e verfasserin |4 aut | |
| 700 | 1 | |a Goswami, Shweta |e verfasserin |4 aut | |
| 700 | 1 | |a Das, Asim |e verfasserin |4 aut | |
| 700 | 1 | |a Dwivedi, Tanima |e verfasserin |4 aut | |
| 700 | 1 | |a Sharma, Nandini |e verfasserin |4 aut | |
| 700 | 1 | |a Kumar, Suresh |e verfasserin |4 aut | |
| 700 | 1 | |a Sharma, Pragya |e verfasserin |4 aut | |
| 700 | 1 | |a Kapoor, Seema |e verfasserin |4 aut | |
| 700 | 1 | |a Kshetrapa, Pallavi |e verfasserin |4 aut | |
| 700 | 1 | |a Wadhwa, Nitya |e verfasserin |4 aut | |
| 700 | 1 | |a Thiruvengadam, Ramachandran |e verfasserin |4 aut | |
| 700 | 1 | |a Kumar, Rakesh |e verfasserin |4 aut | |
| 700 | 1 | |a Gupta, Ritu |e verfasserin |4 aut | |
| 700 | 1 | |a Garg, Pramod Kumar |e verfasserin |4 aut | |
| 700 | 1 | |a Bhatnagar, Shinjini |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Indian journal of medical research |d 1945 |g 157(2023), 6 vom: 01. Juni, Seite 509-518 |w (DE-627)NLM000030619 |x 0971-5916 |7 nnns |
| 773 | 1 | 8 | |g volume:157 |g year:2023 |g number:6 |g day:01 |g month:06 |g pages:509-518 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.4103/ijmr.ijmr_2521_22 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 157 |j 2023 |e 6 |b 01 |c 06 |h 509-518 | ||